Meet KDBIO at the 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to discuss production of “difficult-to-express” mAbs and other proteins using continuous high density cell culture for more “in-vivo like” culture conditions. https://events.marketsandmarkets.com/4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress/
Save my name, email, and website in this browser for the next time I comment.
The HFS-TB is proposed for use in optimization of drug regimens and dose selection to maximize the bactericidal and sterilizing effect rates and minimize the emergence of resistance. When used early in the drug development cycle as a complementary and additional tool to existing methodologies, information regarding optimal dose selection, dosing schedules and potential combination therapies can be obtained. Additionally, the HFS-TB can be used in a post-approval setting to optimize currently used drug regimens (for both dose and dosing schedule) for drug-susceptible and drug-resistant TB. Therefore, the results obtained by the HFS-TB are expected to support trial design for Phase I, II, III and IV clinical trials.